Emily Drabant Conley is currently the CEO of Nuvalent, Inc., a biotech company focused on developing innovative treatments. She brings a wealth of experience from her previous roles, including serving as the CEO of Federation Bio, where she led projects...

Emily Drabant Conley is currently the CEO of Nuvalent, Inc., a biotech company focused on developing innovative treatments. She brings a wealth of experience from her previous roles, including serving as the CEO of Federation Bio, where she led projects in microbial cell therapies across various diseases. Emily also worked for over a decade at 23andMe, a company recognized for personal genomics. In her current role, she has achieved significant results, with her performance goals exceeding expectations in 2023, earning her a bonus that reflects her impact on the company's direction. She joined Nuvalent’s board of directors in February 2022 and was appointed CEO later that year. Emily holds an M.B.A. and has been acknowledged in several influential lists, showcasing her prominence in the biotech industry. Her decisions at Nuvalent are backed by a strong focus on research and development, aligning strategic goals with company success, making her a key player in advancing biotechnology.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Nuvalent, Inc. CEOs

N

Emily Conley

CEO of Nuvalent, Inc.

Education

M.B.A.

Field of Expertise

Business & Management

Sector of Economy

Healthcare

CEO of Nuvalent, Inc. for

3 years 2 months (Feb 2022 - Present)

Previous Experience

Former director at multiple biotech firms

Rivals

Competitors/colleagues of Emily Conley

Holdings

See how much did Emily Conley make over time.

As the CEO of Nuvalent, Emily Conley holds a significant position in the company's stock but did not report any vested stock in 2023. Interestingly, her total compensation increased to $669,256 due to the successful achievement of corporate performance targets,...

As the CEO of Nuvalent, Emily Conley holds a significant position in the company's stock but did not report any vested stock in 2023. Interestingly, her total compensation increased to $669,256 due to the successful achievement of corporate performance targets, which were met at 130% of the goal. Though she joined the board in 2022, her stock holdings reflect a level of investment in Nuvalent, signaling her belief in the company's direction and potential. This marks a notable shift from the previous year when she reported no bonuses or stock grants, indicating a strong performance in 2023 that aligns with her leadership strategy. The commitment to the company is evident as her financial involvement has grown, suggesting confidence in Nuvalent's future.

Total Stock Sold

$2.84M

NUVL

$2.84M

36,667 NUVL shares

What if they kept their stock?

If Emily Conley didn't sell their stock, today they would have:
Extra NUVL36,667 shares worth $687.51K.
This is -75.82% and $2.16M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Emily Conley.

NUVL

$283.46K

NUVL at $85.02/share

Aug 23, 2024

Sale

NUVL

$403.81K

NUVL at $80.76/share

Jul 15, 2024

Sale

NUVL

$389.57K

NUVL at $77.91/share

Jun 14, 2024

Sale

NUVL

2,499 shares

NUVL

Jun 12, 2024

Received

NUVL

$345.45K

NUVL at $69.09/share

May 15, 2024

Sale

NUVL

$330.45K

NUVL at $66.09/share

Apr 15, 2024

Sale

NUVL

$1.09M

NUVL at $81.69/share

Mar 15, 2024

Sale

Compensation History

See how much did Emily Conley make over time.

In 2023, Emily Conley's total compensation was $669,256, comprised primarily of her salary of $440,300 and a performance-based bonus of $228,956, reflecting a 130% achievement of her corporate goals. This was a notable increase compared to 2022 when no bonuses or stock options were reported. Her set compensation aligns with the company’s philosophy to attract and retain top talent by rewarding executives based on performance metrics that are heavily tied to significant corporate objectives. The absence of vested stock or stock grants during this period indicates a focus on direct compensation rather than equity for the time being, yet demonstrates her engagement in driving the company's success directly, underlining her position as a proactive leader in the biotech field.

Year

2023

Total Compensation

$669.26K

Salary

$440.30K

Board Justification

The compensation philosophy is designed to attract and retain qualified executives, motivate them to achieve business goals, and reward them for performance, aligning their interests with those of stockholders.

Bonus

$228.96K

Board Justification

The bonus is based on the achievement of certain corporate performance milestones, with a target annual bonus of 40% of her base salary. For 2023, the corporate performance goals were achieved at 130% of target.

Other

$0.00

Board Justification

No other compensation was reported for 2023.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for determining compensation are based on corporate performance goals related to research and development programs.

Other Nuvalent, Inc. CEOs

Here are other CEOs of Nuvalent, Inc.

Anna Protopapas

CEO of Nuvalent, Inc.

March 2022 - Present